Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06855394 · ClinicalTrials.gov registry record
Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events
A clinical trial of Stroke and Heart Diseases, sponsored by University of Florida.
- Active
- Registry status
- 13,000
- Enrollment target
- 2
- Study locations
NCT06855394 is a study of Stroke and Heart Diseases that is active but no longer recruiting, run by University of Florida. The registered enrollment target is 13,000 participants, roughly in line with the 11,988-participant average among 454 other Stroke trials with a reported enrollment target. The trial reports 2 study locations across 1 state.
The verdict
NCT06855394, a study of Stroke and Heart Diseases, is active but no longer recruiting, sponsored by University of Florida.
- ACTIVE NOT RECRUITING
- Registry status
- 13,000 participants
- Enrollment target
- 2
- Study locations
Study Summary
Several studies have shown that the efficacy of clopidogrel for secondary prevention of major adverse cardiovascular events (MACE), including acute coronary syndrome, depends on the polymorphism of the CYP2C19 gene. However, studies with large sample sizes and long-term follow-up are missing. Moreover, the impact of this polymorphism on the risk of major adverse limb events (MALE), particularly in patients with peripheral artery disease of the lower limb, is unexplored. Additionally, the impact of CYP2C19 gene polymorphism on clopidogrel effectiveness in preventing recurrent stroke in diverse populations is unknown since most of the data are from Asian ancestry populations. We hypothesize that patients with CYP2C19 gene loss of function alleles are at high risk of MACE and MALE compared to those without loss of function alleles at long-term follow-up. We propose to assess MACE and MALE in a large cohort of patients with available CYP2C19 genotypes treated at the University of Florida Health to evaluate the impact of CYP2C19 gene polymorphisms on the risk of new or recurrent events at long-term follow-up. Our specific aims are Aim 1) to determine the impact of CYP2C19 gene polymorphisms (loss of function alleles vs. non-loss of function alleles) on the risk of MACE (a composite of all-cause death, non-fatal MI, and non-fatal stroke) at long-term follow-up; Aim 2) to evaluate the impact of CYP2C19 gene polymorphisms (loss of function alleles vs. non-loss of function alleles) on the risk of MALE (a composite of limb amputations, chronic threatening limb ischemia, acute limb ischemia, and limb revascularization) at long-term follow-up; and Aim 3) to evaluate the impact of CYP2C19 gene polymorphisms (loss of function alleles vs. non-loss of function alleles) on the risk of cerebrovascular events (CVE, a composite of any stroke and transient ischemic attack) at long-term follow-up.
Conditions Studied
Study Locations (2)
Florida
- UF Health - Gainesville
- UF Health - Jacksonville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 13,000 participants |
| Start Date | 2011-01-01 |
| Est. Completion | 2025-12-31 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06855394
The ClinicalTrials.gov registry entry for NCT06855394 describes a study currently listed as active not recruiting, categorized as an unspecified phase. The registered enrollment target is 13,000 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 11,988-participant average among 454 other Stroke trials with a reported enrollment target. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 7 conditions, with Stroke appearing as the primary indexed condition, and to 0 interventions.
NCT06855394 reports 2 study locations spanning 1 distinct geographic area - top geographies include Florida.
Frequently Asked Questions
What is clinical trial NCT06855394 about?
NCT06855394 is a clinical study titled "Genetic Testing of CYP2C19 in Prognostic Evaluation of Long-Term Major Adverse Cardiac and Vascular Events". Several studies have shown that the efficacy of clopidogrel for secondary prevention of major adverse cardiovascular events (MACE), including acute coronary syndrome, depends on the polymorphism of the CYP2C19 gene. However, studies with large sample sizes and long-term follow-up are missing. Moreov...
What is the current status of trial NCT06855394?
This trial is currently active not recruiting. The enrollment target is 13,000 participants. The study started on 2011-01-01. Estimated completion is 2025-12-31.
What conditions does trial NCT06855394 study?
This clinical trial studies the following conditions: Stroke, Heart Diseases, Coronary Arterial Disease (CAD), Venous Thromboembolic Disease, Atherosclerotic Vascular Disease.
Who is sponsoring clinical trial NCT06855394?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06855394 being conducted?
This trial has 2 study locations across Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Stroke
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
The SLEEPR Study: SLEep Effects on Post-stroke Rehabilitation
RECRUITING
-
Tracking a Tactile Signal Along the Nervous System
RECRUITING · NA
-
Transcranial Direct Current Stimulation (tDCS) With Verb Network Strengthening Treatment (VNeST) in Chronic Aphasia
RECRUITING · NA
-
Genetic and Environmental Risk Factors for Hemorrhagic Stroke
RECRUITING
-
Strategy Training for Individuals With Unilateral Neglect
RECRUITING · NA
-
Weight Loss and ExeRcise
RECRUITING · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.